Treatment Delays for Metastatic Breast Cancer Vary by Race
Black and Hispanic patients with de novo metastatic breast cancer experience significant delays in treatment initiation compared with White patients. Delays were observed in endocrine therapy, chemotherapy, and radiotherapy across different subtypes of breast cancer.
A study of 117,743 female patients with de novo metastatic breast cancer (dnMBC) in the US found racial disparities in treatment initiation. Black patients faced delays of 6.6 days in endocrine therapy and 11.3 days in radiotherapy for hormone receptor-positive disease. Hispanic patients experienced delays of 8.3 days and 18.6 days, respectively. The study analyzed data from the National Cancer Database between 2010 and 2022. Medicaid enrollment, Medicare enrollment, and lack of insurance were associated with delayed treatment initiation. The authors emphasize the need for tailored interventions to improve care delivery and outcomes.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.